Publications by authors named "Byung-Hee Oh"
Article Synopsis
- Cachexia and sarcopenia are prevalent in heart failure patients, negatively affecting their survival, prompting this study to explore how serum creatinine levels relate to mortality in acute heart failure patients.
- The study included 5,198 acute heart failure patients, categorized by serum creatinine levels into five groups, with a focus on post-discharge all-cause mortality and finding a J-shaped relationship between creatinine levels and mortality rates.
- Results revealed that both low (<0.6 mg/dL) and high creatinine levels increased mortality risk, with low levels raising the risk of all-cause mortality by 33% after accounting for various health factors.
Article Synopsis
- The study investigates the eligibility of heart failure patients for dapagliflozin and its cost-effectiveness compared to standard therapy, using data from the Korean Acute Heart Failure registry.
- About 48.7% of the patients met eligibility criteria from previous clinical trials, with higher eligibility found in those with preserved ejection fraction.
- Dapagliflozin was found to be cost-effective, especially for patients with a left ventricular ejection fraction of 40% or less, showing a significant benefit in quality-adjusted life years at a cost well below standard willingness-to-pay thresholds.
Article Synopsis
- The FDA and EMA approved empagliflozin for reducing cardiovascular mortality and heart failure hospitalization in patients with HFrEF and HFpEF, but its real-world applicability is unclear.
- A study analyzing data from the Korean Acute Heart Failure (KorAHF) registry found that 91.4% of patients met FDA/EMA criteria, while only 44.7% met trial criteria.
- Empagliflozin was determined to be cost-effective at $6,764 per quality-adjusted life year (QALY), particularly for HFrEF patients ($5,012 per QALY), indicating potential benefits in clinical settings in South Korea.
Aims: Although the hypothesis that metformin is beneficial for patients with diabetes and heart failure (HF) has been steadily raised, there is limited data on metformin use in patients with acute HF. We analyzed the association of metformin on all-cause mortality in hospitalized patients with type 2 diabetes and acute HF.
Methods: The Korean Acute Heart Failure registry prospectively enrolled patients hospitalized for acute HF from 2011 to 2014.
Background: High C-reactive protein (CRP) levels are associated with poor outcomes of heart failure (HF), and statins are known to reduce CRP levels. We investigated the prognostic value of CRP and statin in patients with HF with reduced and preserved ejection fraction (EF).
Methods: Altogether, 3,831 patients from the Korean Acute Heart Failure registry were included and stratified according to the tertiles of CRP levels (T1: CRP < 0.
Background: High glycemic variability (GV) is a poor prognostic marker in cardiovascular diseases. We aimed to investigate the association of GV with all-cause mortality in patients with acute heart failure (HF).
Methods: The Korean Acute Heart Failure registry enrolled patients hospitalized for acute HF from 2011 to 2014.
We aimed to conduct the largest study evaluating the impact of cardiac troponin (TnI) status on mid- and long-term mortality in patients admitted for acute heart failure (AHF) as compared between patients with ischemic (IHF) vs. non-ischemic heart failure (non-IHF). Among 5625 patients from the Korea Acute Heart Failure (KorAHF) registry, 4396 eligible patients with TnI measurement were analyzed.
View Article and Find Full Text PDF[This corrects the article DOI: 10.3389/fcvm.2022.
View Article and Find Full Text PDFBackground: The prognostic impact and predictors of NOAF in HF patients are not fully elucidated. This study aims to determine whether new-onset atrial fibrillation (NOAF) affects patient outcome and investigate predictors of atrial fibrillation (AF) in acute heart failure (HF) patients using real-world data. Methods: The factors associated with NOAF in 2894 patients with sinus rhythm (SR) enrolled in the Korean Acute Heart Failure (KorAHF) registry were investigated.
View Article and Find Full Text PDFPurpose: Although renal failure is a major healthcare burden globally and the cornerstone for preventing its irreversible progression is an early diagnosis, an adequate and noninvasive tool to screen renal impairment (RI) reliably and economically does not exist. We developed an interpretable deep learning model (DLM) using electrocardiography (ECG) and validated its performance.
Methods: This retrospective cohort study included two hospitals.
Background: Randomized clinical trials of spironolactone showed significant mortality reduction in patients with heart failure with reduced ejection fraction. However, its role in acute heart failure syndrome (AHFS) is largely unknown.
Aim: To investigate the prescription characteristics, efficacy and safety of spironolactone in real-world patients with AHFS.
Aims In 2021, vericiguat was approved by the US Food and Drug Administration (FDA) and the European Commission (EC) for reducing cardiovascular mortality and heart failure (HF) hospitalizations in patients with HF with reduced ejection fraction (HFrEF) based on the Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction (VICTORIA) trial. However, there has been no report for characterizing the generalizability of vericiguat to real-world clinical practice. Methods and results The Korean Acute Heart Failure (KorAHF) registry is a multicentre prospective cohort study.
View Article and Find Full Text PDFA dose-response relationship of renin-angiotensin system blockers and beta-blockers in patients with acute heart failure syndrome: a nationwide prospective cohort study.
Eur Heart J Cardiovasc Pharmacother
September 2022
Aims: It remains unclear if patients with acute heart failure syndrome (AHFS) need to reach the maximally tolerated doses of renin-angiotensin system blockers (RASBs) or beta-blockers (BBs) to obtain a survival benefit. This study evaluated the dose-response relationship between RASBs or BBs and survival in AHFS patients.
Methods And Results: In total, 5331 patients in the Korean Acute Heart Failure registry were analysed based on the doses of RASBs and BBs at discharge.
Aims: A waiting period of more than 3 months is recommended for patients before undergoing cardiac resynchronization therapy (CRT). However, due to an anticipated high mortality rate, early implementation of CRT might be beneficial for some patients. We aimed to evaluate the rate and the probability of left ventricular (LV) function improvement and their predictors in patients with heart failure (HF) with indications for CRT.
View Article and Find Full Text PDFObjective: Machine learning (ML) algorithm can improve risk prediction because ML can select features and segment continuous variables effectively unbiased. We generated a risk score model for mortality with ML algorithms in East-Asian patients with heart failure (HF).
Methods: From the Korean Acute Heart Failure (KorAHF) registry, we used the data of 3683 patients with 27 continuous and 44 categorical variables.
Article Synopsis
- Early detection and intervention of arrhythmia is vital for effective treatment and reducing complications, prompting the development of an explainable deep learning model (XDM) for classification.
- Utilizing a large dataset of 86,802 electrocardiograms (ECGs), the XDM was validated against external data from 36,961 ECGs to ensure its accuracy and explainability.
- The XDM demonstrated high performance with area under the curve (AUC) scores of 0.976 and 0.966 during internal and external validation, respectively, indicating it could classify arrhythmias effectively while providing explanations for its classifications, enhancing its usefulness in clinical settings.
Aims: Tachycardia is a reversible event that may cause hemodynamic decompensation but may not necessarily cause direct damages to the myocardium. To evaluate the clinical outcomes of patients with heart failure (HF) and atrial fibrillation (AF), whose acute decompensation was tachycardia mediated.
Methods And Results: The Korean Acute Heart Failure registry was a prospective registry that consecutively enrolled 5625 patients with acute HF.
Evidence for effectiveness of early change from angiotensin II receptor blockers (ARBs) or angiotensin-converting enzyme inhibitors (ACEIs) to sacubitril/valsartan is lacking. We aimed to investigate whether early changes to sacubitril/valsartan could improve outcomes in patients with nonischemic dilated cardiomyopathy (DCM) in real-world practice. : A total of 296 patients with nonischemic DCM who were treated with ARB or ACEI continuously (group A, = 150) or had their medication switched to sacubitril/valsartan (group S, = 146) were included.
View Article and Find Full Text PDFAims: In this study, we integrated two randomized control trials, PROSPECTIVE and IMPACT, to address the effect of probucol on cerebrocardiovascular events and carotid intima-media thickness (IMT) in Japanese, Korean, and Chinese patients with coronary artery disease (CAD).
Methods: A total of 1,025 patients from the PROSPECTIVE and IMPACT studies were enrolled. The time to the first major adverse cerebrocardiovascular event, in addition to carotid IMT and lipid levels, was compared between the control and probucol groups.
Artificial intelligence for detecting electrolyte imbalance using electrocardiography.
Ann Noninvasive Electrocardiol
May 2021
Introduction: The detection and monitoring of electrolyte imbalance is essential for appropriate management of many metabolic diseases; however, there is no tool that detects such imbalances reliably and noninvasively. In this study, we developed a deep learning model (DLM) using electrocardiography (ECG) for detecting electrolyte imbalance and validated its performance in a multicenter study.
Methods And Results: This retrospective cohort study included two hospitals: 92,140 patients who underwent a laboratory electrolyte examination and an ECG within 30 min were included in this study.
Although heart failure with reduced ejection fraction (HFrEF) is a common clinical syndrome and can be modified by the administration of appropriate medical therapy, there is no adequate tool available to perform reliable, economical, early-stage screening. To meet this need, we developed an interpretable artificial intelligence (AI) algorithm for HFrEF screening using electrocardiography (ECG) and validated its performance. This retrospective cohort study included two hospitals.
View Article and Find Full Text PDFAims: Paroxysmal supraventricular tachycardia (PSVT) is not detected owing to its paroxysmal nature, but it is associated with the risk of cardiovascular disease and worsens the patient quality of life. A deep learning model (DLM) was developed and validated to identify patients with PSVT during normal sinus rhythm in this multicentre retrospective study.
Methods And Results: This study included 12 955 patients with normal sinus rhythm, confirmed by a cardiologist.
Background: Anaemia is an important health-care burden globally, and screening for anaemia is crucial to prevent multi-organ injury, irreversible complications, and life-threatening adverse events. We aimed to establish whether a deep learning algorithm (DLA) that enables non-invasive anaemia screening from electrocardiograms (ECGs) might improve the detection of anaemia.
Methods: We did a retrospective, multicentre, diagnostic study in which a DLA was developed using ECGs and then internally and externally validated.
Aims: Although heart failure with preserved ejection fraction (HFpEF) is a rapidly emerging global health problem, an adequate tool to screen it reliably and economically does not exist. We developed an interpretable deep learning model (DLM) using electrocardiography (ECG) and validated its performance.
Methods And Results: This retrospective cohort study included two hospitals.